Substance Use Disorder Long-Acting Injectables: Naltrexone and Buprenorphine

Substance Use Disorder Long-Acting Injectables: Naltrexone and Buprenorphine is organized by American Association of Psychiatric Pharmacists (AAPP).

Activity Dates: 05/31/2023 - 05/15/2026

Session Summary:
This webinar focuses on important factors related to use of LAIs for substance use disorders, such as target patient populations, indications, product preparation, dosing, administration techniques, adverse effects, storage requirements, and monitoring recommendations.

This is one of six modules in the Psychotropic LAI Training Program. Complete your complimentary registration now to access this module, 5 other ACPE approved modules, a LAI Pocket Guide, administration videos, and an Administrative Toolkit.

Learning Objectives:

• Describe dosing and administration, including product preparation, for naltrexone long acting injectable (LAI) and buprenorphine LAI.
• Identify contraindications, warnings/precautions, common adverse effects and potential mitigation strategies for naltrexone LAI and buprenorphine LAI.
• Describe the storage requirements and stability data of naltrexone LAI and buprenorphine LAI.
• Outline a plan for monitoring and follow up of a patient receiving naltrexone LAI or buprenorphine LAI.